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Background: Cyclophosphamide plus thalidomide as induction for multiple myeloma
patients eligible for autologous stem cell transplantation may be a limiting factor for cell
mobilization. The minimum acceptable mobilized peripheral blood stem cell count to pre-
vent  deleterious effects during transplantation is 2.0 × 106 CD34+ cells/kg. Combining other
treatments to granulocyte-colony stimulating factor, such as cyclophosphamide, could over-
come the mobilization limitation. The objective of this study was to assess the number
of  CD34+ cells mobilized using granulocyte-colony stimulating factor with and without
cyclophosphamide after induction with cyclophosphamide, thalidomide and dexametha-
sone.
Methods: A retrospective study was performed of a cohort of multiple myeloma patients
submitted to autologous stem cell transplantations at two Brazilian centers between May
2009  and July 2013. The oral cyclophosphamide and thalidomide induction doses used were
1500  mg/month and 100–200 mg/day, respectively. Mobilization doses were 10–15 mcg/kg
granulocyte-colony stimulating factor with 2–4 g/m2 cyclophosphamide, or 15–20 mcg/kg
granulocyte-colony stimulating factor alone for 5 days. Collection of >2.0 × 106 CD34+ cells/kg
cient.was  considered sufﬁResults: Eighty-eight patients were analyzed; only 18 received cyclophosphamide. The
median age was 58 years old (range: 51–62) for the granulocyte-colony stimulating fac-
tor  group and 56.5 years old (range: 54–60) for granulocyte-colony stimulating factor plus
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cyclophosphamide group. Fifty-two patients were male. Eighty cases (90.9%) were Durie-
Salmon Staging System III-A/B and 38 (44.7%) and 20 cases (23.5%) were International
Staging System 2 and 3, respectively. The group that received cyclophosphamide collected
a  higher median number of progenitor cells [3.8 (range: 3.1–4.4) vs. 3.2 (range: 2.3–3.8)]
(p-value = 0.008). No correlation was observed between better responses or number of induc-
tion  cycles and the number of cells collected.
Conclusion: The number of cells mobilized with granulocyte-colony stimulating factor plus
cyclophosphamide was higher. However, in both groups, the median number of CD34+ cells
was  sufﬁcient to perform a single autologous stem cell transplantation; no deleterious
effects were reported during harvesting.
©  2016 Associac¸a˜o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by  Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1, 8 and 15, thalidomide (100 mg/day) and dexamethasonentroduction
he use of high-dose chemotherapy plus autologous stem cell
ransplantation (ASCT) as consolidation after chemotherapy
nduction has been the ﬁrst line of treatment for eligible mul-
iple myeloma patients for over three decades.1 Currently,
he most commonly employed induction strategy is to use
 number of cycles (4–6) with three drugs.1 The introduc-
ion of triple combinations of novel agents for induction,
uch as the immunomodulators thalidomide and lenalido-
ide or the proteasome inhibitor bortezomib, has signiﬁcantly
hanged as these drugs resulted in better outcomes and tol-
rability compared to classic regimens such as vincristine,
oxorubicin and dexamethasone (VAD).1 However, the induc-
ion regimens should not affect hematopoietic progenitors
n the mobilization process.2–6 Recently, this inﬂuence on
obilization has been gaining increased attention due to the
se of chemotherapy combinations involving novel agents
uch as immunomodulators (lenalidomide) and, in particu-
ar, alkylating agents (cyclophosphamide) which can increase
ematologic toxicity.2,6 Auner et al.2 found that the combina-
ion of cyclophosphamide, thalidomide and dexamethasone
CTD) in the induction of patients with multiple myeloma sig-
iﬁcantly reduced mobilization of progenitor cells compared
o the classic VAD or VAD-like regimens, even when using
yclophosphamide in association with granulocyte colony-
timulating factor (G-CSF) during mobilization. In an effort
o overcome this mobilization problem, other agents have
een associated with G-CSF, most notably plerixafor.7 How-
ver, the high cost of plerixafor limits its use in many
enters. Chemotherapy associated with G-CSF can signiﬁ-
antly increase the mobilization of progenitor cells. One of
he most used chemotherapy drugs in mobilization based on a
ombination with G-CSF is cyclophosphamide, administered
t a typical dose of 2–4 g/m2.8 However, this treatment has
ome drawbacks given that it raises the cost of the proce-
ure owing to the need for hospitalization of patients and
an lead to slower bone marrow engraftment, greater toxic-
ty with pancytopenia, neutropenia, infections and death.9–12
he number of CD34+ collected for ASCT depends on sev-
ral factors the most important of which are the number of
ransplantations planned and the least impact in terms oftime on the mobilized peripheral blood stem cells. Tradition-
ally, the target for CD34+ cell collection for single ASCT has
been 4–6 × 106 cells/kg, with the value also hinging on the
deleterious impact of harvesting at counts of below 2 × 106
CD34+ cells/kg, deﬁned as the lowest acceptable level.3 Greater
numbers of CD34+ cells have not been associated with any sig-
niﬁcant beneﬁt in the parameters studied.6 Another objective
in the quantity of cells mobilized is to allow for a cell reserve
for a second ASCT as rescue in the event of future disease
relapse, rendering the target cell count in the ﬁrst mobilization
≥4 × 106 CD34+ cells/kg.8,13 Some peculiarities exist in Brazil
which hamper the use of ASCT such as low number of beds
for transplantations and the shortage of frozen cell storage
for second transplants within the Brazilian National Health
System (SUS). The three-drug induction regimen widely used
in Brazil for multiple myeloma patients is cyclophosphamide,
thalidomide and dexamethasone (CTD).14 The primary objec-
tive of this study was to determine whether the collection
of progenitor cells using G-CSF alone is sufﬁcient to per-
form at least one ASCT, compared with a group undergoing
mobilization with G-CSF associated with cyclophosphamide,
in patients submitted to the CTD chemotherapy regimen for
induction.
Methods
A retrospective, sequential analysis of 88 multiple myeloma
patients who had been mobilized for peripheral blood stem
cell harvest and submitted to ASCT at two Brazilian centers
between May 2009 and June 2013 was conducted. All patients
were induced using the CTD regimen. Center 1, Hospital da
Irmandade da Santa Casa de Misericórdia de São Paulo, used
a continuous infusion of cyclophosphamide (50 mg/day), a
continuous infusion of thalidomide (100–200 mg/day) and
dexamethasone (160 mg/month). Center 2, Hospital das
Clinicas of the Faculdade de Medicina da Universidade de
SP (HC-FMUSP), used cyclophosphamide (500 mg)  on Days(200–400 mg/month). All the agents were administered orally
with four to six planned induction cycles. The protocol used
for mobilization differed between the centers giving two
groups for comparison: Group 1 received cyclophosphamide
oter.
was 28.6 months and the overall PFS was 24 months. No
signiﬁcant difference was found between the two  groups.
Median PFS was 25.7 months for the G-CSF alone group and
the PFS had not been attained for the group that received
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(2–4 g/m2 split in 2 doses) associated with G-CSF (10–15 mcg/kg
until the collection of cells), and Group 2 received G-CSF
(15–20 mcg/kg for 5 days) alone. All patients were submitted
to an outpatient mobilization protocol. The CD34+ cell count
for collection was determined by ﬂow cytometry using a
FACSCalibur BD device with double platform and employing
the cell quest program and ISHAGE protocol. Apheresis was
performed according to the CD34+ count in peripheral blood
(≥10 × 103/mL) starting between Day 7 and 10 in Group 1 and
Day 4 and 10 in Group 2, with the median day of collection
being Days 7 and 4 after commencing G-CSF for Groups 1 and
2, respectively. The patients were submitted to a large volume
leukapheresis protocol with a median of four blood volume
apheresis (range: 3–6). The Cobe® Spectra Marc Terumo
BCT apheresis system was used in both centers. CD34+ cell
collection was considered adequate with a count ≥2.0 × 106
CD34+ cells/kg. As the CD34+ cells for the transplants had
come from patients who had their cells collected previously,
it was not possible to analyze data on failure of mobilization.
Progression-free survival (PFS) and overall survival (OS) were
analyzed. PFS was deﬁned as the time elapsed between the
start of induction treatment to disease progression or death,
with censure on the date of last contact. OS was deﬁned as the
time elapsed between the start of induction treatment until
death, with censure on the date of last contact. The unpaired
t-test was used to compare means of variables with a normal
distribution, whereas the Mann–Whitney test was employed
to compare variables with a non-normal distribution. Cate-
gorical variables, including response rates, were compared
using the Chi-square or Fisher exact tests, as applicable.
Survival analyses were carried out using the Kaplan–Meier
technique while the comparison between groups was per-
formed with the log rank test. Median follow-up for OS was
calculated using the reverse Kaplan–Meier method. Analyses
were carried out using the MedCalc software (Mariakerke,
Belgium, v. 11.3.3.0). Values with a two-tailed p-value <0.05
were considered statistically signiﬁcant. The study protocol
was approved by both institutions, with data collected from
a database derived from the Grupo Brasileiro de Mieloma
Múltiplo (GBRAM 003) study. This study was approved by the
Research Ethics Committee of the Hospital da Irmandade da
Santa Casa de Misericórdia de São Paulo and a consent form
was waived given the retrospective nature of the study.
Results
Demographic  and  baseline  clinical  characteristics  of
patients
A total of 88 patients with multiple myeloma submitted to
ASCT after induction using CTD were included. Regarding the
mobilization scheme, 70 patients received ﬁlgrastim alone,
and 18 received a combination of ﬁlgrastim and cyclophos-
phamide. The main demographic and clinical characteristics
of the 88 patients stratiﬁed by mobilization scheme are shown
in Table 1. The groups did not differ in respect to age (median:
58; range: 51–62 years) or gender and the groups were balanced
in terms of performance status or prognostic index using
the Durie-Salmon Staging System (DSS) and International 2 0 1 6;3  8(4):302–309
Staging System (ISS). Table 2 depicts the distribution of the
main laboratory variables at the time of diagnosis. No signif-
icant difference was found between the groups for any of the
variables studied. Given the retrospective nature of the study,
there was a large amount of missing data for some variables
(total calcium, ionized calcium, creatinine, lactate dehydroge-
nase (LDH), Beta-2 microglobulin) in the group submitted to
mobilization using G-CSF alone.
Mobilization  of  progenitor  cells
The data on the number of CD34+ collected was available for
all patients, whereas the number of days of apheresis required
for collection was available for only 77 cases. The group receiv-
ing G-CSF alone harvested a mean of 3.4 ± 1.3 × 106/kg and a
median of 3.2 × 106/kg (range: 2.3–3.8 × 106/kg) of CD34+ cells.
On the other hand, the group that received ﬁlgrastim com-
bined with cyclophosphamide harvested a higher number of
progenitor cells with a mean of 6.4 ± 7.7 × 106/kg and median
of 3.8 × 106/kg (range: 3.1–4.4 × 106/kg) (p-value = 0.008). No sig-
niﬁcant difference in the number of days for collection was
observed between the groups (p-value = 0.077). A summary of
the number of cells mobilized and days of apheresis for the
two groups is shown in Table 3.
Pre-transplant  response  rates,  number  of  chemotherapy
cycles,  quantity  of  cells  mobilized  and  adverse  events
related  to  the  mobilization  protocol
The mobilized CD34+-cell count was not inﬂuenced by the
number of chemotherapy cycles administered, nor by the
response rate prior to ASCT (Figure 1 and Table 4). No  adverse
events were recorded in the database register for the group
that received cyclophosphamide associated with G-CSF.
Overall  survival  for  the  two  groups
At the time of analysis, 39 of the 88 patients had suffered
disease progression, and four had died. The median follow-upNumber cycles
Figure 1 – Relationship between number of chemotherapy
cycles on induction and number of CD34+ cells collected.
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Table 1 – Patient characteristics.
Variables G-CSF G-CSF plus Cyclophosphamide p-Value
Age at start of treatment – years
n 80 18
Range 36–69 42–68 0.933
Mean ± SD 56.2 ± 7.3 56.4 ± 6.5
Median (IQR) 58 (53–61) 56.5 (54–60)
Gender – n (%)
n 80 18
Female 31 (44.3) 5 (27.8) 0.284
Male 39 (55.7) 13 (72.2)
Ig subtype – n (%)
n 80 18
IgG K/L 30 (42.8) 9 (50) NS
IgA K/L 9 (12.8) 4 (22.2)
Light 7 (10) 4 (22.2)
Other/not analyzed 24 (34.2) 1 (5.6)
Performance status – n (%)
n 44 14
0 19 (43.2) 7 (50.0) 0.944
1 8 (18.2) 2 (14.3)
2 11 (25.0) 4 (28.6)
3 5 (11.4) 1 (7.1)
4 1 (2.3) 0
Osseous lesion – n (%)
n 39 6
No 8 (20.5) 5 (83.3) 0.005
Yes 31 (79.5) 1 (16.7)
DSS – n (%)
n 70 18
IIA 7 (10.0) 1 (5.6) 0.769
IIIA 53 (75.7) 15 (83.3)
IIIB 10 (14.3) 2 (11.1)
ISS – n (%)
n 68 17
1 23 (33.8) 4 (23.5) 0.678
2 29 (42.7) 9 (52.9)
3 16 (23.5) 4 (23.5)
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Staging System.
ssociated cyclophosphamide (Figure 2). Similarly, no differ-
nce was observed between the two groups for OS. Median OS
ad not been attained in either of the groups. The hazard ratio
or OS was 0.65 (95% conﬁdence interval: 0.18–2.27) favoring
he cyclophosphamide regimen but not reaching signiﬁcance
p-value = 0.495) (Figure 3).
iscussion
he aim of the present study was to analyze the quantity
f mobilized progenitor cells with the use of G-CSF alone
r in combination with the chemotherapy agent cyclophos-
hamide, in patients with newly diagnosed multiple myeloma
ubmitted to chemotherapy induction using the CTD protocol.
his is the ﬁrst analysis of its kind published in the litera-
ure. The target quantity of mobilized cells differs between
enters as some plan double ASCT, or allow for the freezing of
ome cells for a second transplant in the event of relapse while: interquartile range; DSS: Durie-Salmon Staging; ISS: International
other centers plan collections for a single ASCT. Patients sub-
mitted to ASCT are generally over the age of 65 years where
age ≥65 years has been identiﬁed as a predictive factor for
poor mobilization.15,16 The median age of the patients in this
study was 58 (range: 36–69) years, with no signiﬁcant differ-
ence between the groups and therefore without predisposition
to mobilization problems. Regarding clinical characteristics,
there was a difference between the groups for the num-
ber of bone lesions, which was higher in the G-CSF group
(p-value = 0.005). More advanced disease stage has also been
reported as a factor that negatively affects mobilization.16
No signiﬁcant difference was found between the groups in
relation to the DSS and ISS staging or performance status.
Another factor identiﬁed as a risk factor for harvesting is the
pre-mobilization tumor load.17 This load can be indirectly
assessed based on the degree of response after induction.
In the current study, there was no real advantage on com-
paring the quantity of mobilized cells for different response
rates. The induction chemotherapy protocol for patients with
306  rev bras hematol hemoter. 2 0 1 6;3  8(4):302–309
Table 2 – Laboratory variables.
Variable G-CSF G-CSF plus Cyclophosphamide p-Value
Hemoglobin – g/dL
n 66 18
Mean ± SD 9.6 ± 2.5 9.7 ± 1.6 0.972
Creatinine – mg/dL
n 54 18
Mean ± SD 1.2 ± 0.8 1.5 ± 1.4 0.443
Median (IQR) 0.9 (0.7–1.5) 1.05 (0.8–1.5)
Total calcium – mg/dL
n 49 18
Mean ± SD 9.9  ± 1.6 10.2 ± 1.7 0.099
Median (IQR) 9.3 (9.0–10.1) 9.75 (9.6–10.6)
Ionized calcium – mol/L
n 22 17
Mean ± SD 5.6  ± 2.0 5.5 ± 0.7 0.955
Median (IQR) 5.3 (4.9–6.5) 5.3 (5.2–5.6)
ˇ2-microglobulin – mg/L
n 51 17
Mean ± SD 4.3 ± 3.2 7.3 ± 7.1 0.128
Median (IQR) 3.3 (2.2–5.4) 3.8 (3.0–7.5)
C-reactive protein – mg/dL
n 29 15
Mean ± SD 13.6 ± 25.5 22.8 ± 50.2 0.063
Median (IQR) 2.3 (0.4–11.9) 7.2 (3.3–16.2)
LDH – U/L
n 27 18
Mean ± SD 278 ± 193 335 ± 181 0.320
Albumin – g/dL
n 45 18
Mean ± SD 3.6 ± 0.7 3.5 ± 0.6 0.840
M component – g/dL
n 25 18
Mean ± SD 3.6 ± 2.2 4.9 ± 3.1 0.136
Plasmocytes – %
n 55 18
Mean ± SD 40.7 ± 27.0 41.0 ± 32.4 0.960
ase; G-CSF: granulocyte-colony stimulating factor; LDH: lactic dehydrogen
multiple myeloma eligible for ASCT varies between centers
worldwide in terms of type and combination of the agents
employed. There is a strong, almost universal tendency for
the use of novel agents such as bortezomib, lenalidomide and
Table 3 – Quantity of mobilized cells and days of apheresis for t
regimens.
Variable G-CSF 
Cell count – ×106/kg
n 70 
Mean ± SD 3.4 ± 1.3 
Median (IQR) 3.2 (2.3–3.8) 
Apheresis – days
n 60 
Mean ± SD 1.5 ± 0.6 
Median (IQR) 1 (1–2) 
G-CSF: granulocyte-colony stimulating factor.M component: monoclonal component.
thalidomide, as combinations or with corticosteroids and/or
alkylating agents.18–21 The use of a combination of three drugs
in induction as opposed to two drugs yields greater beneﬁts in
response and survival.1 In Brazil, the only agent available for
he G-CSF and G-CSF plus cyclophosphamide mobilization
G-CSF/Cyclophosphamide p-Value
18
6.4 ± 7.7 0.008
3.8 (3.1–4.4)
17
1.2 ± 0.5 0.077
1 (1–1)
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Table 4 – Relationship between response type on induction and number of mobilized cells.
Response type and time point Response No response p-Value
After four cycles ≥ PR
Cell count – ×106/kg n = 74 n = 14
Mean ± SD 4.2 ± 4.1 3.1 ± 0.8 0.176
Median (IQR) 3.35 (2.7–4.0) 3.15 (2.3–3.3)
Pre-aHSCT ≥ PR
Cell count – ×106/kg n = 80 n = 8
Mean ± SD 4.1 ± 4.0 3.3 ± 0.8 0.780
Median (IQR) 3.3 (2.6–4.05) 3.3 (2.95–3.55)
After four cycles ≥ VGPR
Cell count – ×106/kg n  = 36 n  = 52
Mean ± SD 5.0 ± 5.6 3.4 ± 1.4 0.228
Median (IQR) 3.35 (2.95–5.25) 3.3 (2.35–3.8)
Pre-aHSCT ≥ VGPR
Cell count – ×106/kg n = 47 n = 41
Mean ± SD 4.6  ± 5.0 3.4  ± 1.5 0.135
Median (IQR) 3.4  (3.025–4.275) 3.2 (2.3–3.825)
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se in the public health system is thalidomide. The best com-
ination identiﬁed and widely used in Brazilian centers is the
TD protocol. Currently, centers in developed countries pre-
er to use other drugs for induction however, combinations
ith thalidomide are still in use in Brazil and in other devel-
ping countries. This protocol was compared in a randomized
hase III study against the VAD plus cyclophosphamide regi-
en  in over 1000 patients with the CTD arm providing better
esponse rates.20 The patients studied in the present inves-
igation were selected from two national centers that use
ifferent protocols for the use of cyclophosphamide. How-
ver, the ﬁnal monthly dose (1500 mg)  is the same in both:
enter 1 uses a continuous daily oral dose of 50 mg;  Center 2
ses a dose of 500 mg/week for three weeks every 28 days. In
he only study published assessing the effect on mobilization
Progression-free survival
Number at risk
Group: 1
70 48 33 10 3 1
18 14 5 3 0 0
Group: 2
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igure 2 – Progression-free survival for G-CSF and
-CSF + cyclophosphamide groups.ponse; VGPR: very good partial response.
in patients undergoing CTD, Auner et al.2 reported mobiliza-
tion failure in attempts to perform at least one ASCT. Failure
rates for cell number cut-offs of ≥4 × 106 CD34+ cells/kg and
of ≥2 × 106 CD34+ cells/kg were 39% and 25% of the cases,
respectively. In another study comparing CTD vs. a regimen
of VAD plus cyclophosphamide as induction, Morgan et al.
identiﬁed a mobilization failure rate of 1% of cases.19 In these
studies, the combination of G-CSF and cyclophosphamide was
used for mobilization in all cases. Transplant centers differ
with regard to the standard conduct for harvesting progen-
itor cells. The use of cyclophosphamide, while promoting
better cell collection, prolongs the whole process due to the
wait for cell production recovery. Generally, this process is
performed with the patient hospitalized and is associated
with increased risk of febrile neutropenia and other infectious
Overall survival
Number at risk
Group: 1
70 53 41 23 10 1
18 16 8 4 0 0
Group: 2
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Figure 3 – Overall survival for G-CSF and
G-CSF + cyclophosphamide groups.
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complications.6 For both of the centers in the present analy-
sis, the minimum acceptable number of collected cells was
2 × 106 CD34+ cells/kg, thereby allowing for at least one ASCT
to be carried out. A difference between groups was noted
for the mobilization of progenitor cells, with the group that
received G-CSF plus cyclophosphamide harvesting a higher
mean of 6.4 (±7.7) × 106/kg vs. 3.4 (±1.3) × 106/kg for the group
that received G-CSF alone (p-value = 0.008). However, the num-
ber of cells in both groups was sufﬁcient to perform at least
one ASCT. Auner et al. reported a different number of days
of apheresis in cases that received CTD vs. those induced
using a VAD or VAD-like protocol. In the current study, no
difference in the number of days of apheresis was observed
between the groups (p-value = 0.07). No studies exist that sup-
port an increase in induction time preceding mobilization to
enhance successful cell collection.22 In the present study, no
association was found between better response and improved
survival. The cyclophosphamide used in mobilization, in addi-
tion to its ability to promote release of progenitor cells from
the bone marrow for peripheral collection, has a reputation
of reducing the disease further (debulking) during the collec-
tion of progenitor cells. Retrospective studies have failed to
conﬁrm this effect and have shown no advantage in terms of
survival.22 Similarly, in the present study, no advantages of
cyclophosphamide use were found in terms of mobilization,
improved response or survival. Assessing the situation in the
Brazilian context with regards to limitations for performing
ASCT, difﬁculties in frozen storage of cells, and the need to
cut costs, the present study revealed that sufﬁcient progenitor
cells can be mobilized to perform at least one ASCT with the
use of G-CSF alone in patients induced using the CTD protocol.
Conclusion
The use of G-CSF alone to mobilize progenitor cells is feasible
in multiple myeloma patients induced with a cyclophos-
phamide, thalidomide and dexamethasone protocol.
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